Immunology and Biotherapies
17.0K views | +12 today
Follow
 
Scooped by Gilbert C FAURE
onto Immunology and Biotherapies
Scoop.it!

Cellular & Molecular Immunology - Attenuated Listeria ... - Rss - Nature

Cellular and Molecular Immunology aims to report the dynamic progress being made in China and abroad in immunological research, and welcomes high-quality Research Articles, Reviews and Brief Reports across a broad ...
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

No evidence for the use of stem cell therapy for tendon disorders: a systematic review

No evidence for the use of stem cell therapy for tendon disorders: a systematic review | Immunology and Biotherapies | Scoop.it
Introduction Stem cells have emerged as a new treatment option for tendon disorders. We systematically reviewed the current evidence for stem cell therapy in tendon disorders.

Methods Randomised and non-randomised controlled trials, cohort studies and case series with a minimum of 5 cases were searched in MEDLINE, CENTRAL, EMBASE, CINAHL, PEDro and SPORTDiscus. In addition, we searched grey literature databases and trial registers. Only human studies were included and no time or language restrictions were applied to our search. All references of included trials were checked for possibly eligible trials. Risk of bias assessment was performed using the Cochrane risk of bias tool for controlled trials and the Newcastle-Ottawa scale for case series. Levels of evidence were assigned according to the Oxford levels of evidence.

Results 4 published and three unpublished/pending trials were found with a total of 79 patients. No unpublished data were available. Two trials evaluated bone marrow-derived stem cells in rotator cuff repair surgery and found lower retear rates compared with historical controls or the literature. One trial used allogenic adipose-derived stem cells to treat lateral epicondylar tendinopathy. Improved Mayo Elbow Performance Index, Visual Analogue Pain scale and ultrasound findings after 1-year follow-up compared with baseline were found. Bone marrow-derived stem cell-treated patellar tendinopathy showed improved International Knee Documentation Committee, Knee injury and Osteoarthritis Outcome Score subscales and Tegner scores after 5-year follow-up. One trial reported adverse events and found them to be mild (eg, swelling, effusion). All trials were at high risk of bias and only level 4 evidence was available.

Conclusions No evidence (level 4) was found for the therapeutic use of stem cells for tendon disorders. The use of stem cell therapy for tendon disorders in clinical practice is currently not advised.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Angioedema suppressed by a combination of anti-histamine and leukotriene modifier. - PubMed - NCBI

Angioedema suppressed by a combination of anti-histamine and leukotriene modifier. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Allergy Asthma Clin Immunol. 2017 Jun 13;13:28. doi: 10.1186/s13223-017-0201-1. eCollection 2017.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Infections from 7 clinical trials of ixekizumab, an anti-interleukin-17a monoclonal antibody, in patients with moderate-to-severe psoriasis

Infections from 7 clinical trials of ixekizumab, an anti-interleukin-17a monoclonal antibody, in patients with moderate-to-severe psoriasis | Immunology and Biotherapies | Scoop.it
Internal Medicine Article: Infections from 7 clinical trials of ixekizumab, an anti-interleukin-17a monoclonal antibody, in patients with moderate-to-severe psoriasis
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

NF-Κ54;B Inhibitors in Head and Neck Cancer: Ingenta Connect

NF-Κ54;B Inhibitors in Head and Neck Cancer Authors: Nagini, Siddavaram; Kiran Kishore Tanagala, Kranthi; Chattopadhyay, Indranil Source: Letters in Drug Design & Discovery, Volume 14, Number 5, May 2017, pp.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Sanofi to invest further in biologics

PARIS, June 14 (Reuters) - French drugmaker and healthcare group Sanofi on Wednesday announced plans to invest 600 million euros ($673 million
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Webinar: Modeling NAFLD and TGFbeta-induced Fibrosis in ExVive™ Human Liver Tissue

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder with an estimated prevalence of over 25% worldwide and is projected to becom
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. - PubMed - NCBI

Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
JAMA Dermatol. 2017 May 31. doi: 10.1001/jamadermatol.2017.1162. [Epub ahead of print]
more...
No comment yet.
Rescooped by Gilbert C FAURE from Biotech Pharma Innovation in Immuno-Oncology & beyond. Cancer - Immunology - Immunotherapy.
Scoop.it!

Manufacturing costs loom large for personalized CAR-T cancer meds and their need for speed

Manufacturing costs loom large for personalized CAR-T cancer meds and their need for speed | Immunology and Biotherapies | Scoop.it
Manufacturing quality and costs always play some part in the cost of a new drug, but they are the elephant in the room when looking at CAR-T, personalized cancer medications now under development. That is because of the extensive process to genetically code a patient’s T cells to hunt and kill cancer cells, along with the need for speed.  

Instead of grabbing a medicine off the shelf or even infusing a mass-produced biologic at a doctor’s office, the process requires that blood be taken from a patient, cryopreserved, shipped to a facility, reprogrammed and manufactured in the lab, and then shipped back for infusion into the patient, all in the shortest time possible to try to outrun aggressive cancers.

Novartis and Kite, which have the two leading CAR-T candidates, have not provided much insight into pricing. They have, however, given glimpses into their manufacturing and the turnaround times they will need to treat patients for lymphomas.

RELATED: How will Novartis price its groundbreaking CAR-T med? R&D exec offers some clues

Novartis talked about manufacturing after it released data on its candidate last week, which will be reviewed by an advisory committee July 12. Novartis officials said that the Swiss company expects to have the turnaround time for its treatment down to 22 days at the time of commercial launch, with 10 to 12 of those days being “the actual cell processing time.”

RELATED: As Novartis preps for first CAR-T FDA AdComm, Juliet data revealed

Santa Monica, California-based Kite says its time is even shorter, although not the 14 days it had initially striven for. “Our manufacturing process delivery time—what we call vein to vein—is between 16 to 18 days,” a spokeswoman said in an email. “This is from the time of leukapheresis to when the cells are back with the clinician for infusion into the patient. This includes 6 to 7 days needed for the cell engineering, as well as quality control and travel time.”

She said the biotech is looking for ways to speed the process further and points out that its manufacturing success rate during clinical trials was 99%.

Novartis is claiming that with continuous process improvements over the course of its Juliet trial, its manufacturing success rate improved to 97% for the last 30 patients. That followed some early issues in which 9 of 141 patients, or 6%, had to discontinue treatment due to “an inability to manufacture an adequate dose of CAR-T cells.”

The company says it has gotten on top of the complicated process. It is now being overseen by Spencer Fisk, who took over as global head cell & gene technical development and manufacturing in Morris Plains, New Jersey, after Karen Walker departed several months ago for a position with Seattle Genetics.

“As for manufacturing, we are confident we will be able to meet the required manufacturing demands moving forward,” a Novartis spokesperson told FierceBiotech last week.

Novartis also has an agreement with the Fraunhofer Institute for Cell Therapy and Immunology for the cell processing of its personalized T cell therapy in Europe.

Kite is producing its chimeric antigen receptor (CAR) and T-cell receptor (TCR) candidate in a new 43,500-square-foot plant it purposely built next to an airport. The plant is estimated to have the capacity to produce up to 5,000 patient therapies per year.

RELATED: Kite Pharma opens CAR-T cell manufacturing plant next to LA airport

Novartis converted to its use a plant built by the former Dendreon, which used a similar process of altering cells for its once-promising prostate cancer vaccine Provenge. Dendreon sold its 173,000-square-foot plant in Morris Plains, one of three, to Novartis in 2012 for $43 million to pick up some fast cash.

Dendreon’s experience hangs over this new manufacturing method since the company went bankrupt trying to establish Provenge. Its cost of goods at one point was 77%, before it dropped that to about 53% with process changes. That compares to about 10% for many biotechs.

RELATED: Dendreon, done in by expensive, complex manufacturing, files for bankruptcy

While Dendreon failed to find a price point to compete with established, mass-produced drugs, makers of the new cancer drugs will have the luxury of setting a foundational price for their treatments, which have the potential to be curative.

Neither Kite or Novartis have offered any hard guidance on pricing, but Novartis R&D chief Vas Narasimhan has told Bloomberg that stem cell treatment prices could offer a benchmark. Stem cell transplants and follow-up treatment can cost upwards of $800,000. He also said the company is looking at pay-for-performance deals.

Via Dominique Blanchard
more...
No comment yet.
Rescooped by Gilbert C FAURE from Biotech Pharma Innovation in Immuno-Oncology & beyond. Cancer - Immunology - Immunotherapy.
Scoop.it!

Celgene bags option on NK cell-based blood cancer assets | FierceBiotech

Celgene bags option on NK cell-based blood cancer assets | FierceBiotech | Immunology and Biotherapies | Scoop.it
Celgene has landed an option on four natural killer (NK) cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics. The agreement sees Celgene hand over $33 million and commit to more in milestones to access next-generation immuno-oncology candidates aimed at some of its core therapeutic areas.

Cambridge, Massachusetts-based Dragonfly has given Celgene the exclusive option to license up to four assets designed to treat acute myeloid leukemia, multiple myeloma and other hematological cancers. The candidates will emerge from a platform that Dragonfly sees establishing NK cell alongside T cells as a critical component of the push to weaponize the immune system to defeat cancers. Celyad and Innate Pharma have landed deals on the strength of their own attempts to use NK cells.

Dragonfly’s platform generates bridges designed to bind to proteins found on the surface of tumor cells and NK cells. The aim is to stimulate NK cells. Once activated and aware of the presence of the cancer cells, NK cells attack tumors directly while also enlisting the support of T and B cells. T cells, the cornerstone of current immuno-oncology approaches, then join the direct attack on the tumor, while B cells produce antibodies to help the fight against the cancer. 

Via Dominique Blanchard
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Autoimmunity Reviews


Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review o
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Regulatory T cells: tolerance induction in solid organ transplantation

Regulatory T cells: tolerance induction in solid organ transplantation | Immunology and Biotherapies | Scoop.it
The concept of regulatory T cell (Treg) therapy in transplantation is now a reality. Significant advances in science and technology have enabled us to isolate human Tregs, expand them to clinicall
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Bone Marrow Transplantation - Cord blood transplantation: rewind to fast forward

Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Novartis’ heart drug canakinumab meets primary endpoint in phase III study - Pharmaceutical Business Review

Novartis’ heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos)
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Personalized T cell-mediated cancer immunotherapy: progress and challenges

Personalized T cell-mediated cancer immunotherapy: progress and challenges | Immunology and Biotherapies | Scoop.it
Highlights • Patient-specific mutated neoantigens are important targets of anti-tumor immunity. • Personalized immunotherapies that target neoantigens may be safer and more effective. • Personalizing T cell-mediated immunotherapies will require efficient platforms for neoantigen and T cell receptor discovery. • TCR repertoire analysis may be an inroad for identifying targets of immunity against low mutational burden cancers. • Personalized immunotherapies present novel regulatory and logistical challenges.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, June 21, 9:12 AM
Current Opinion in Biotechnology Volume 48, December 2017, Pages 142–152
https://doi.org/10.1016/j.copbio.2017.03.024
Personalized T cell-mediated cancer immunotherapy: progress and challenges 
 Michael T Bethune , Alok V Joglekar
Scooped by Gilbert C FAURE
Scoop.it!

ScienceDirect

Publication date: 18 May 2017
Source:Cell, Volume 169, Issue 5
Author(s): Seiya Yamayoshi, Yoshihiro Kawaoka
Ebola virus disease poses a global health threat. Here, two studies by Wec et al. and Zhao et al. identified vulnerability in an internal fusion loop of an ebolavirus glycoprotein. Monoclonal antibodies elicited from immunization and isolated from a human survivor that recognized epitopes in this area neutralized all five ebolaviruses, guiding the development of a pan-ebolavirus immunotherapy.
Teaser Ebola virus disease poses a global health threat. Here, two studies by Wec et al. and Zhao et al. identified vulnerability in an internal fusion loop of an ebolavirus glycoprotein. Monoclonal antibodies elicited from immunization and isolated from a human survivor that recognized epitopes in this area neutralized all five ebolaviruses, guiding the development of a pan-ebolavirus immunotherapy.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

PD-L2 Helps Predict Immunotherapy Responsiveness for Head and Neck Cancer | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN

PD-L2 Helps Predict Immunotherapy Responsiveness for Head and Neck Cancer | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN | Immunology and Biotherapies | Scoop.it
PD-L2 protein expression in human tumors was associated with clinical response to pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, independent of PD-L1 expression
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Viral vectors travel longer distances than previously thought

Viral vectors travel longer distances than previously thought | Immunology and Biotherapies | Scoop.it
Gene transfer is seen as a hopeful therapy for Alzheimer's and Parkinson's patients. The approach involves using harmless laboratory-produced viruses to introduce important genes into the brain cells. In a study on mice
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

EMA Adopts a Negative Opinion for Human IgG1 mAb Specific for Human Interleukin-1 Alpha XBiotech | ESMO

This medicine was intended to treat debilitating symptoms of advanced colorectal cancer
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Frontiers | Editorial: Antibody Repertoire and Graft Outcome following Solid Organ Transplantation | Immunology

Editorial: Antibody Repertoire and Graft Outcome following Solid Organ Transplantation
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions
Gilbert C FAURE's insight:
Nature Immunology (2017) doi:10.1038/ni.3770 Received 16 March 2017 Accepted 16 May 2017 Published online 12 June 2017
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The Era of Immunotherapeutics: Overcoming the Challenges to Fulfill the Potential - Industry Insights | Elsevier Whitepaper

By boosting anti-cancer response using a patient’s own immune system, immunotherapeutics are showing incredible promise
more...
No comment yet.
Rescooped by Gilbert C FAURE from Melanoma BRAF Inhibitors Review
Scoop.it!

Epigenetics and immunotherapy: The current state of play

Epigenetics and immunotherapy: The current state of play | Immunology and Biotherapies | Scoop.it
Highlights • Epigenetic immunomodulation plays a key role tumour immune escape. • Epigenetic therapy can prime and sensitise the host immune response to subsequent immunotherapeutic strategies. • Combined epigenetic and immunotherapy holds significant promise for improved patient outcomes in many different cancer types.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, June 12, 3:53 AM
Molecular Immunology Volume 87, July 2017, Pages 227–239 
Epigenetics and immunotherapy: The current state of play Jennifer Dunn , Sudha Rao, https://doi.org/10.1016/j.molimm.2017.04.012
Scooped by Gilbert C FAURE
Scoop.it!

Monoclonal Antibodies and the Fight Against Cancer

Monoclonal Antibodies and the Fight Against Cancer | Immunology and Biotherapies | Scoop.it
The body produces millions of antibodies, each uniquely designed to target specific pathogens: bacteria, viruses, and other parasitic invaders. Antibodies recognize and bind the pathogen, sen
more...
No comment yet.